Scalper1 News
The FDA on Thursday afternoon approved Vertex Pharmaceuticals’ (VRTX) potential blockbuster cystic-fibrosis drug Orkambi, which the company priced at $259,000 per year, on the high side of investors’ expectations. The agency gave the nod to Orkambi, a combination of ivacaftor (which Vertex markets separately as Kalydeco) and lumacaftor, a booster that makes the drug effective in treating a much larger population than ivacaftor alone. The FDA Scalper1 News
Scalper1 News